Granted Patent B1

US 12,350,194 · App. 17/069,404 · Granted Jul 8, 2025

Inventors: Mark S. Blumenkranz (Portola Valley, CA); Daniel V. Palanker (Sunnyvale, CA); Yehuda Ivri (Newport Coast, CA); Casey Dougan (San Mateo, CA); Reynaldo Quintana (Menlo Park, CA)

Assignee: BAUSCH + LOMB IRELAND LIMITED

A61F9/0026G16H20/13G16H40/67

Abstract

Claims (30)

1. A method of treating a subject for an ophthalmic condition, the method comprising:

providing a micro-dose having a known mass of a therapeutic agent wherein the microdose has a volume of about 5 μl to about 10 μl;

administering to an ocular surface within a palpebral fissure of the subject the micro-dose such that the known mass of the therapeutic agent is deposited on the ocular surface,

wherein the micro-dose is administered by a handheld dispenser that comprises:

i) a single container comprising a liquid formulation of the therapeutic agent in direct fluid communication with a single aperture;

ii) an actuator configured to emit the micro-dose from the container as a collimated stream of liquid through the single aperture, the single aperture having a diameter of 200 μm to 350 μm, wherein the stream diameter ranges from about 0.2 to about 0.5 mm, wherein an administered velocity of the stream is higher than an exit velocity of the stream, wherein the exit velocity is about 20 cm/sec to about 250 cm/sec; and

iii) a wireless communication unit for information exchange with one or more external devices.

2. The method of claim 1 , wherein the wireless communication unit transfers dose tracking information to an external receiver selected from the group consisting of: smart phones, tablets and computers.

3. The method of claim 2 , wherein the dose tracking information includes delivered micro-dose(s) encoded by one or more actuator parameters selected from the group consisting of: driving voltage, driving current, frequency and pulse duration.

4. The method of claim 1 , wherein the actuator is a piezoelectric actuator or an electromagnetic actuator and wherein the wireless communication unit can receive information from the one or more external devices for controlling actuator parameters.

5. The method of claim 1 , wherein the wireless communication unit is bi-directional, whereby it can transfer information about the administered microdose(s) from the handheld dispenser to the one or more external devices, and also receive information for controlling actuator parameters.

6. The method of claim 5 , wherein the micro-dose(s) can be adjusted from the one or more external devices by the subject or by a physician or by a medical service provider.

7. The method of claim 1 , wherein the micro-dose is self-administered by the subject or is administered by another person.

8. The method of claim 1 , further comprising providing a security feature in the handheld dispenser that limits who can use, access, and/or control the device.

9. The method of claim 1 , wherein the subject employs the image-based alignment system to align the aperture with the ocular surface.

10. The method of claim 1 , further comprising automatically providing dose reminders to the subject.

11. The method of claim 1 , further comprising automatically providing compliance monitoring via the wireless communication unit.

12. The method of claim 1 , wherein the handheld dispenser includes a display.

13. The method of claim 1 , further comprising automatically monitoring a remaining amount of the therapeutic agent in the handheld dispenser.

14. The method of claim 13 , further comprising alerting the subject when the remaining amount of the therapeutic agent in the handheld dispenser falls below a predetermined alert level.

15. The method of claim 13 , further comprising automatically refilling a prescription of the therapeutic agent when the remaining amount of the therapeutic agent in the handheld dispenser falls below a predetermined prescription refill level.

16. The method of claim 1 , further comprising tracking immediate and/or cumulative total dispensed mass dose of the therapeutic agent by the handheld dispenser.

17. The method of claim 1 , further comprising providing a remote connection to a medical service provider.

18. The method of claim 1 , further comprising adjusting dosage of the therapeutic agent based on coordination of the administered dose mass with one or more outcome measures.

19. The method of claim 18 , wherein the outcome measures are selected from the group consisting of: intraocular pressure measurements, visual acuity measurements, eye images of the subject, measures of therapeutic results and measures of adverse reactions.

20. The method of claim 1 , further comprising adjusting dosage of the therapeutic agent by mass according to a physician's discretion.

21. The method of claim 20 , wherein the subject is not aware of dosage of the therapeutic agent by mass as prescribed by a physician as part of a clinical trial protocol.

22. The method of claim 21 , wherein a medical service provider can actively and remotely adjust mass dosage of the therapeutic agent that the subject receives as part of a clinical trial protocol.

23. The method of claim 1 , further comprising automatically tracking a current date in relation to an expiration date of the therapeutic agent and preventing use of the therapeutic agent after the expiration date.

24. The method of claim 1 , wherein a volume of the microdose corresponds to the fluid volume capacity of the eye surface such that the volume can be wholly accommodated on the ocular surface.

Assignments (8)

Continuity (10)

References Cited (364)